Senseonics' Q2 2025: Key Contradictions on Revenue Growth, Eon Care Expansion, and Patient Retention Rates

Consignment channel and revenue growth, Eon Care expansion and implanter increase, retention rates and economic factors, patient mix and market opportunity, retention rates and patient behavior are the key contradictions discussed in Senseonics' latest 2025Q2 earnings call.



Eversense 365 Launch Momentum:
- In Q2 2025, Senseonics saw new patient starts for Eversense 365 increase by 79% year-over-year and 37% from Q1.
- The growth in new patient starts was driven by expanded DTC marketing efforts, including hiring new sales reps and increased awareness of Eversense's unique attributes.

CMS Payment Update and Consignment Program:
- CMS updated the physician fee schedule to provide payment for a full year of Eversense, which led to an increase in business through the consignment program.
- The consignment program accounted for over 40% of Q2 revenue, with the percentage expected to increase due to Medicare reimbursement and Eon Care expansion.

R&D and Product Pipeline:
- Senseonics raised approximately $78 million in Q2 to support ongoing Eversense 365 launch and R&D efforts, particularly for the Gemini and Freedom programs.
- The company is on track to start an IDE pivotal study for Gemini later this year, with a U.S. submission planned for mid-2026 and a commercial launch expected by the end of 2026.

Eon Care Network Expansion:
- As of Q2, the Eon Care network consists of nearly 40 practitioners, handling approximately 20% of Eversense 365 insertions.
- The company aims to expand the network to 50 practitioners by the end of 2025 and 100 by the end of 2026, enhancing insertion depth and breadth across major U.S. geographies.